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We describe a simple protocol for the preparation and orthogonal hydrophobic/hydrophilic LC–MS/MS
analysis of mouse and human plasma samples, which enables the untargeted (‘‘shotgun’’) or targeted pro-
ﬁling of hydrophilic, amphipathic, and hydrophobic constituents of plasma metabolome. The protocol is
rapid, efﬁcient, and reliable, and offers several advantages compared to current procedures. When
applied to a training set of human plasma samples, the protocol allowed for the rapid acquisition of full
LogP metabolic proﬁles in plasma samples obtained from cognitively healthy human subjects and age-
matched subjects with mild cognitive impairment or Alzheimer’s disease (n = 15 each). Targeted analyses
conﬁrmed these ﬁndings, which are consistent with data previously published by other groups.
 2014 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Despite its irreplaceable role in biomarker discovery, blood
plasma presents multiple unresolved challenges for metabolo-
mics-based analysis. Three key factors contribute to the analytical
complexity of this biological matrix: (i) the occurrence of interfer-
ing proteins, (ii) the vast chemical diversity of its small-molecule
constituents, and (iii) the wide range of concentrations at which
such constituents are present. The removal of proteins from plasma
has been achieved using a variety of approaches [1,2]. These include
‘‘two-phase’’ extraction, in which proteins are precipitated with a
water-miscible organic solvent (e.g., methanol or acetonitrile) and
then eliminated by centrifugation; solid phase extraction by low-
pressure chromatography; and ‘‘three-phase’’ extraction [3], in
which polar and apolar analytes are differentially separated using
a combination of water-miscible and water-immiscible organic sol-
vents (e.g., methanol and chloroform) [3]. Each of these approaches
presents distinct advantages and limitations. For example,
two-phase extraction methods are fast, inexpensive, and reliable,
but often yield samples that contain substantial amounts ofphospholipids, peptides, and small proteins. Solid-phase extraction,
on the other hand, generates samples that are enriched in speciﬁc
classes of analytes, but is inappropriate when the objective is met-
abolomic proﬁling. A compromise solution is represented by three-
phase extraction methods, which are used for the extraction of
plasma metabolites with a broad range of polarities. In addition
to these well-known approaches, the use of paper as a solid support
for the extraction of small molecules from blood or plasma has
recently attracted a great deal of interest [4–6]. This strategy is
not immediately suitable for high throughput implementation,
but has already reached routine laboratory analysis thanks to its
efﬁciency and reliability. An additional factor that contributes to
the analytical complexity of human plasma is the remarkable qual-
itative and quantitative diversity of the chemical entities found in
this biological matrix. The current version of the Human Metabolo-
me Database (3.5) reports that human blood contains 4528 differ-
ent compounds [7,8]. From an analytical perspective, this
diversity implies that a broad spectrum of analyte polarities (with
LogP values ranging from <2 for sugars and basic aminoacids to
>10 for triacylglycerols) and concentrations (from millimolar to
femtomolar) must be taken into consideration. This represents, in
turn, a considerable obstacle to LC–MS-based analyte identiﬁcation
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ited linearity range of MS detectors. A case in point is provided by
the phospholipid (PC),1 which is highly abundant in human plasma
and displays a high ionization efﬁciency in positive ESI-MS: the abil-
ity of the phosphoryl-choline headgroup of PC to generate strongMS/
MS ion currents (at m/z = 184.07) interferes with the detection and
quantiﬁcation of many coeluting plasma components. The present
study describes a protocol that enables the rapid shotgun proﬁling
of plasma analytes of broadly different polarities. Plasma samples
collected from mice or human subjects are separated into three
fractions using a slight variation of the three-phase Bligh–Dryer
extraction [3]. The fractions are then subjected to an orthogonal
two-column/three-gradient chromatographic procedure on reversed-
phase or HILIC columns [9,10]. The protocol permits the exploration
of a polarity space that ranges from sugars (LogP < 2) to triacylgly-
cerols (LogP > 10). The results of a nontargeted application of the
present protocol to human subjects with neurodegenerative demen-
tia, which were conﬁrmed by subsequent targeted analyses, are in
good agreement with literature data documenting the existence of
sphingolipid alterations in plasma of cognitively impaired people.Materials and methods
Human subjects
We included 45 male and 45 female subjects [30 with Alzhei-
mer’s Disease (AD), 30 with mild cognitive impairment (MCI),
and 30 cognitively healthy controls] from the MCI/AD Italian pre-
vention project [11,12] aimed at studying cognitive and neuropsy-
chiatric symptoms and disorders in patients with MCI and AD, at
the IRCCS Santa Lucia Foundation memory clinic in Rome, Italy.
Table 1 shows the socio-demographic and clinical characteristics
of the three groups of AD, MCI, and healthy controls separately
for males and females. There were no differences among the three
groups in age and gender. All subjects underwent examination
between January 2008 and January 2012, including a thorough
clinical neurological and psychiatric examination and extensive
cognitive assessment, and were included at ﬁrst diagnosis of the
disease, and before treatment with psychotropic drugs or acetyl-
cholinesterase inhibitors; patients who received such medications
were excluded from the study. A thorough clinical examination
was used to exclude patients with secondary cognitive deﬁcits
due to somatic disorders such as unbalanced diabetes, coronary
heart disease, or other major medical illnesses causing secondary
cognitive impairment. Patients with potential vascular impairment
were excluded if they had Hachinski Ischemic scale score > 4 or
MRI evidence of white matter lesions identiﬁed through consensus
by a neuropsychologist expert in neuroimaging and a neuroradiol-
ogist. Cognitive impairment on the tests was deﬁned using norma-
tive data for the Italian population [13], with speciﬁc age and
educational norms. Diagnosis of AD was made by trained clinical
psychiatrists or neurologists, using criteria consistent with those
outlined by NINCDS–ADRDA [14]. In the current analysis we
included only patients with mini-mental state examination
(MMSE) scoreP 18 and clinical dementia rating (CDR) = 1 to
ensure that only mild AD patients were included. Diagnosis of
MCI was made according to established criteria [11,15] by trained
clinical neurologists and psychologists. The 30 volunteers included
in the control group were recruited from the general population of
the same geographic area (Italian administrative region of Lazio) as
the patients. All controls were living independently in their own1 Abbreviations used: PC, phosphatidylcholine; PE, phosphatidylethanolamine; TG
triacylglycerol; CE, cholesteryl ester; PI, phosphatidylinositol; Cer, ceramide; HILC
hydrophilic interaction liquid chromatography; UPLC, ultra performance liquid
chromatography; XIC, extracted ion current.,
,homes, and performed at a normal level of cognitive functioning in
all neuropsychological tests according to age and education norms
for the Italian population [13]. The nature and purpose of the study
were presented to patients and caregivers, and controls, and writ-
ten informed consent was obtained. The study was approved by
the Ethical Committee of the Santa Lucia Foundation.
Reagents, standards, and instruments
Solvents and chemicalswere purchased fromSigmaAldrich (Milan,
Italy). Mouse plasma was from Tebu-Bio (Le Perray-en-Yvelines,
France) and sphingomyelin standards were from Avanti Polar Lipids
(Alabaster, AL, USA). UPLC/MS and MS/MS systems and columns
were fromWaters (Milford, USA).
Human plasma samples
Blood samples were taken by venipuncture in the morning after
an overnight fast. Blood was collected into 10 ml tubes containing
spray-coated K2EDTA (Vacutainer, Becton Dickinson) and plasma
was obtained by centrifugation at 400g for 15 min, divided into
1 ml sterile cryovials, and then stored at 80 C. Blood drawing
and sample preparation of human plasma samples were carried
out applying the best safety precautions and gloves and goggles
were used for sample handling.
Sample preparation
Human or mouse plasma samples (0.1 ml) were transferred to
glass vials. Liquid–liquid extraction (LLE) was carried out using a
mixture of methanol/chloroform/heptane (2/0.5/0.5 by volume;
0.3 ml). Human plasma samples for shotgun metabolomics analy-
sis were extracted with the same mixture described above but
spiked with unnatural ceramide (d18:1/17:0) at 2 lM concentra-
tion as internal standard for data normalization. After mixing for
30 s with a Vortex, chloroform (0.1 ml) and water (0.1 ml) were
sequentially added, thoroughly stirring after each addition. The
samples were centrifuged for 15 min at 3500g at room tempera-
ture and the acqueous (upper) and organic (lower) phases, sepa-
rated by a protein disk, were collected separately. The upper
phase was split into two equal portions, referred to hereafter as
Fraction C and Fraction B. The lower phase is referred to as Fraction
A. The samples were dried under a stream of N2 and the residues
were dissolved using (a) water containing ammonium formate
(10 mM, adjusted to pH 5 with formic acid; 50 ll) for the analysis
of Fraction C; (b) pure methanol (0.1 ml) for the analysis of Frac-
tion B; and (c) methanol/isopropyl alcohol/chloroform (1/1/1, by
volume; 0.2 ml) for the analysis of Fraction A. After mixing for
30 s, the samples were transferred to glass vials, centrifuged for
10 min at 3500g at room temperature, and transferred to glass
vials for LC–MS/MS analyses. Before injection, Fraction C was
diluted with 50 ll of 10 mM ammonium formate in acetonitrile/
water (95/5, by volume). Blank procedure samples were prepared
exactly as the samples, but replacing plasma with phosphate-buf-
fered saline solution (50 mM). These samples, acquired before and
after each human sample group, were used as quality controls.
Retention time and peak areas of the internal standard were used
to check instrument response variability and retention time shifts.
The amount of plasma used (0.1 ml) enabled several replicate
injections in both ESI+ and ESI ion modes. In some experiments
(solid–liquid-extraction procedure) mouse plasma samples
(0.1 ml, split into 4  25 ll aliquots) were deposited onto Bond
Elut DMS paper (Agilent Technologies, Palo Alto, CA, USA) and
allowed to dry for 1 h at room temperature. The 25 ll spots were
individually cut, transferred to a glass vial, and processed as
described above, with the following modiﬁcations. A methanol/
Table 1
Sociodemographic and clinical characteristics of males and females with Alzheimer’s disease, mild cognitive impairment, and healthy control subjects.
HC MCI AD
Gender Males Females Males Females Males Females
Age 73.3 ± 3.5 73.3 ± 2.3 72.3 ± 3.7 73.1 ± 2.9 73.7 ± 3.0 74.5 ± 3.7
Education 13.4 ± 5.6 10.7 ± 4.0 10.3 ± 4.2 6.7 ± 2.8 9.6 ± 5.3 7.1 ± 4.6
MMSE 28.5 ± 2.0 29.1 ± 1.2 26.5 ± 1.7 26.3 ± 1.8 21.3 ± 4.6 20.0 ± 4.6
Fig.1. Schematic representation of the sample preparation protocol described in
the present study. Each step was designed to emphasize separation between
hydrophobic and hydrophilic analytes. Abbreviations: ACN, acetonitrile; IPA,
isopropanol; LLE, liquid–liquid extraction; SLE, solid–liquid extraction.
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added to the spots and stirred for 30 s on a Vortex. Chloroform
(0.1 ml) and water (0.2 ml) were added, stirring after each addi-
tion. The samples were centrifuged for 15 min at 3500g at room
temperature and the acqueous and organic phases were dried
and resuspended as described above. For comparative experi-
ments, mouse plasma samples (0.1 ml) were subjected to standard
protein precipitation procedures (‘‘crash’’) with organic solvents.
The samples were diluted with acetonitrile or methanol (0.5 ml),
mixed for 30 s with a Vortex, and centrifuged for 15 min at
3500g at room temperature. The supernatants were divided into
three aliquots, dried under N2, and resuspended as described
above.
Liquid chromatography
Analyses were conducted on a UPLC Acquity system coupled to a
Synapt G2 QToF mass spectrometer. Fraction C samples were
loaded onto a 2.1  100 mm HILIC column eluted at 0.4 ml/min.
The following gradient conditions were utilized: A = 10 mM ammo-
nium formate in water, B = 10 mM ammonium formate in 95/5 ace-
tonitrile/water. After 1 min at 100% B, a linear gradient was applied
to 60% B in 11 min, followed by 1 min at 60% B and reconditioning to
100% B. Total run time was 16 min. Fractions B and Awere analyzed
using a C18 T3 column run (2.1  100 mm) at a ﬂow rate of 0.4 ml/
min with acetonitrile and isopropyl alcohol gradient systems,
respectively. The following gradient conditions were utilized. Frac-
tion B: A = 10 mM ammonium formate in water, B = 10 mM ammo-
nium formate in 95/5 acetonitrile/water; after 1 min at 5% B, a
linear gradient was applied to 100% B in 12 min, followed by
1 min at 100% B and reconditioning to 5% B; total run time was
18 min. Fraction A: A = 10 mM ammonium formate in 60/40 aceto-
nitrile/water, B = 10 mM ammonium formate in 90/10 isopropyl
alcohol/acetonitrile; after 1 min at 30%, solvent B was brought to
35% in 3 min, then to 50% in 1 min, and then to 100% in 13 min, fol-
lowed by a 1 min 100% B isocratic step and reconditioning to 30% B.
Total run time was 22 min [16,17]. Injection volume was set at 2 ll
for Fraction A and 5 ll for Fractions C and B.
Mass spectrometry
The capillary voltages were set at 3 and 2 kV for ESI+ and ESI,
respectively. The cone voltages were set at 30 V for ESI+ and 35 V
for ESI, respectively. The source temperature was 120 C. Desolv-
ation gas and cone gas (N2) ﬂow were 800 and 20 L/h, respectively.
Desolvation temperature was 400 C. Data were acquired in MSe
mode [18,19] with MS/MS fragmentation performed in the transfer
region. Low energy scans were acquired at ﬁxed 4 eV potential and
high energy scans were acquired with an energy ramp from 25 to
45 eV. Scan rate was set to 0.3 s per spectrum. Scan range was set
to 50 to 1200m/z. Leucine enkephalin (2 ng/ml) was infused as
lock mass for spectra recalibration.
Analyte identiﬁcation
Analytes were identiﬁed by interrogating the METLIN [20,21],
HMDB [7,8] and LipidMaps [22,23] databases. Tolerance on m/zvalues was set to 3 ppm. Identiﬁcation was based on both accurate
mass and calculated brute formula matching and conﬁrmed with
tandem mass data. LogP data from the HMDB ﬁle of each identiﬁed
metabolite were used.Multivariate data analysis
Raw data from high resolution shotgun metabolomics LC/MS
runs were subjected to principal component analysis (PCA) [24]
using the MarkerLynx software (Waters Inc.). Accurate mass and
retention time data of observed metabolites, previously normal-
ized and realigned using the internal standards peak areas and
retention times, were included in the multivariate analysis and
assigned as X-variables. The following parameters were used to
derive the Scores plots reported in Fig. 4: scan range 100 to 1200
m/z; extracted ion current windows 30 mDa; no smoothing; Pareto
scaling applied; no transformations; maximum 5 components con-
sidered. Orthogonal projection to latent structures discriminant
analysis (OPLS-DA) [25,26] was used to identify metabolites differ-
ently expressed between different experimental groups. GraphPad
Prism software (GraphPad Software, Inc., USA) was used for statis-
tical analyses of targeted data.Targeted sphingomyelin quantiﬁcation
Plasma samples (20 ll) were diluted to 0.1 ml with distilled
water and subjected to sample preparation as described above.
Reconstituted hydrophobic fractions (Fractions A) (5 ll) were ana-
lyzed using a UPLC-Xevo Triple-Quadrupole MS system. Sphingo-
myelin species SM(d18:1/16:0), SM(d18:1/18:0), SM(d18:1/24:0),
Fig.2. Distribution of 20 representative analytes in Fraction A (green), Fraction B (red), and Fraction C (blue). Calculated LogP values are reported on the right of each analyte.
(For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 3. Extraction efﬁciency of the new method, as liquid–liquid extraction (LLE, black) or solid–liquid extraction (SLE, blue) compared to the acetonitrile (red) and methanol
(green) precipitation procedures. The percentage yield was measured using extracted ion currents, with the LLE procedure as reference set at 100%. Experiments were run in
triplicate. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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70% A to 100% B in 6.6 min followed by 1 min at 100% B and recon-
ditioning to 70% A; total run time was 9 min on an ACQUITY UPLC
BEH C18 column (2.1  50 mm) at 0.4 ml/min ﬂow rate (A was
water/acetonitrile 80/20 plus 0.1% formic acid, B was acetonitrile/
isopropyl alcohol 20/80 plus 0.1% formic acid). Sphingomyelin spe-
cies were quantiﬁed on the basis of their MRM traces, using a cal-
ibration curve ranging from 1 nM to 5 lM. The unnatural lipid
(23:0;23:0) PC was included in the extraction process as internal
standard (0.5 lM).Results and discussion
Fig. 1 summarizes the analytical procedure described in the
present report. A slight variation of the classical three-phase
Bligh–Dryer extraction [3] was used to divide plasma samples into
three fractions (termed A, B, and C), whichwere analyzed separately
using either reversed-phase chromatography (Fractions A and B) or
HILIC chromatography (Fraction C) coupled to high-resolution MS/
MS. Fig. 2 illustrates the distribution of 20 representative analytes,
selected on the basis of their biogenetic diversity and chemical
Fig.4. Principal component analysis of plasma samples (Fraction A, ESI+ mode)
from healthy female subjects, female subjects with MCI, and female subjects with
AD (n = 15, matched years: 77 ± 2). (A) Scores plot of samples from AD, MCI, and
age-matched cognitively healthy controls. A moderate separation was observed
between MCI and controls. (B) Scores plot from OPLS-DA analysis of healthy
controls versus MCI patients. (D) Scatter plot of variables (m/z, RT values) showing
increasing contribution to controls (toward bottom left) and MCI patients (toward
top right). Dots corresponding to sphingomyelin species are symbolized with a blue
circle. (For interpretation of the references to color in this ﬁgure legend, the reader
is referred to the web version of this article.)
52 Orthogonal LC-MS for plasma metabolomics / A. Armirotti et al. / Anal. Biochem. 455 (2014) 48–54heterogeneity, in each of the three fractions. Table 2 provides a list
of those analytes along with their MS properties, calculated LogP,
and database reference identiﬁcation. As shown in Fig. 2, Fraction
C was exclusively populated by small hydrophilic molecules, such
as amino acids and phosphorylated glycerols, which eluted from
the HILIC column at water concentrations up to 40%. Fraction B con-
tained midpolarity analytes (from LogP 1.5 to LogP approximately
8), including long-chain fatty acids and hydroxylated fatty acids,
which were effectively separated by reversed-phase chromatogra-
phy (using an acetonitrile gradient) and were detected by MS in
the ESImode. Fraction A included lipids of various polarities, from
amphipathic species such as PC to highly apolar species such as tria-
cylglycerols. We compared the present protocol to methanol and
acetonitrile precipitation procedures widely utilized in metabolo-
mics experiments [27,28]. Extraction yields for each procedure
were estimated based on the sum of XIC peak areas of representa-
tive analytes derived from their chromatographic separations over
the three LC systems. Fig. 3 shows the results of these comparative
tests. For LogP values above 8, our protocol was ostensibly superior
to both acetonitrile and methanol precipitation methods: as
expected, highly apolar lipid species (e.g., TG, PE, CE, and cera-
mides) were not efﬁciently extracted in the absence of a suitable
organic solvent. Our procedure was also superior to two-phase pro-
tein precipitation in the ability to extract highly hydrophilic com-
pounds (LogP < 0). On the other hand, methanol precipitation was
more efﬁcient in extracting amphipathic molecules in the midpo-
larity range, such as fatty acids, PI, and cholesteryl sulfates
(Fig. 3). Interestingly, however, this superiority did not hold for a
solid-supported variant of our method, which provided extraction
yields for these analytes that were comparable to those obtained
using methanol crash. Notably, the addition of triﬂuoroacetic acid
(1%, 5 ll per sample) prior to the liquid extraction markedly low-
ered the amount of lyso-PC present in the acqueous phase after
extraction, thus reducing the risk of ion suppression during LC/MS
analysis. For example, with this simple expedient the spreading of
stearoyl-LysoPC (524.3719 m/z) in LC runs of Fraction A was
reduced from 18 to 1%. As a ﬁrst test of the newly described proce-
dure, we analyzed a training set of human plasma samples obtained
from cognitively healthy elderly female subjects along with an
equal number of samples from age-matched female subjects suffer-
ing from mild cognitive impairment (MCI) or Alzheimer’s disease
(AD) (n = 15 for each group). Shotgun data for Fractions A, B, and
C generated from each subject were acquired in both positive and
negative ion modes. Multivariate data analysis tools were used to
explore the existence of potential differences between the three
groups, using several hundreds of accurate mass/retention time
data pairs as variables for PCA. Though the full LogP range of each
sample was investigated, only representative data are discussed
here. Additional ﬁndings will be discussed in subsequent publica-
tions. Fig. 4A shows the scores plot of Fraction A (apolar phase)
acquired in the positive-ion mode. Samples, clustered by experi-
mental group, are reported in the plot as colored dots (observa-
tions). A clear separation between female subjects with MCI
(green dots) and control subjects (black dots) was noted. Con-
versely, no obvious separationwas observed between subjects with
AD and controls. Control and MCI groups were further compared
using OPLS-DA (Fig. 4B) searching for analytes differentially repre-
sented in the two groups. From the corresponding scatter plot
(Fig. 4C), among various signals that are currently under investiga-
tion, a group of variables, corresponding to several sphingomyelin
species ranging from (d18:1/18:0) to (d18:1/24:1) (blue circle)
appeared to be higher in the control group with respect to MCI.
To further probe these results, which are suggestive of an alteration
in plasma sphingolipid levels in elderly women with MCI, we sub-
jected Fraction A to a targeted analysis using an LC–MS/MS method
Table 2
Representatives analytes present in mouse plasma selected for use as markers in
method evaluation.
Dbase ref. m/z Adduct Analyte LogP
HMDB00517 175.119 [M+H]+ Arginine 3.87
HMDB00122 198.0972 [M+NH4]+ Glucose 2.57
HMDB00086 258.1106 [M+H]+ Glycerophosphocholine 2.56
HMDB00201 204.1233 [M+H]+ Acetylcarnitine 2.39
HMDB00126 171.0057 [MH] Glycerol-3-phosphate 1.84
HMDB00064 132.0771 [M+H]+ Creatine 1.59
HMDB10382 496.3401 [M+H]+ LysoPC(16:0) 1.83
HMDB00653 465.3043 [MH] Cholesteryl sulfate 3.27
LMGP06050006 603.2938 [MH2O+H]+ 1-Arachidonoyl-sn-PI 4.41
HMDB08083 806.5703 [M+H]+ PC(18:1/20:5) 5.75
HMDB02183 327.2329 [MH] Cervonic acid 6.83
HMDB00067 369.3514 [MH2O+H]+ Cholesterol 7.02
HMDB00220 255.2326 [MH] Palmitic acid 7.23
HMDB09816 885.5499 [MH] 1,Stearoyl-
2,arachidonoyl-sn-PI
7.4
HMDB00827 283.2636 [MH] Stearic acid 8.02
HMDB08934 744.5562 [M+H]+ PE(16:0/20:2) 8.82
HMDB06726 690.621 [M+NH4]+ Cholesteryl
arachidonate
10.27
HMDB04956 632.6365 [MH2O+H]+ Ceramide (d18:1/24:0) 10.35
HMDB00918 668.6367 [M+NH4]+ Cholesteryl oleate 10.68
HMDB45105 872.7720 [M+NH4]+ TG(18:0/18:3/16:1) 10.77
The table reports accuratem/z values and MS adduct for each analyte, along with its
LogP value and database reference ID.
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reported in Fig. 5, conﬁrmed that the levels of sphingomyelin
(d18:1/16:0), (d18:1/24:0), and (d18:1/24:1) were signiﬁcantly
lower in plasma of female subjects with MCI compared to age-
matched control subjects. Based on the results of these analyses,
we hypothesized that similar changes might be detectable in
plasma of male subjects. Therefore, we extended our targeted
studies to cognitively healthy elderly male subjects as well as male
subjects with MCI and AD (all 77 ± 2 years old, n = 15 per group).
We found no statistically detectable differences between control
subjects and subjects with MCI (Fig. 5). The analyses did reveal,
however, a difference in the levels of sphingomyelins (d18:1/
16:0), (d18:1/18:0), and (d18:1/24:1) between control subjectsFig.5. Results of targeted LC–MS analyses of various sphingomyelin (SM) species in plasm
control subjects. Data were analyzed using two-way (diagnosis by gender) ANOVAs folland subjects with AD (Fig. 5). To further probe these results, which
are suggestive of an alteration in plasma sphingolipid levels in
elderly women with MCI, we subjected Fraction A to a targeted
analysis using an LC–MS/MS method devised to quantify plasma
sphingomyelin species in both males and females. We used four
separate two-way analyses of variance (ANOVAs) to highlight over-
all differences in d18:1/16:0, d18:1/18:0, d18:1/24:0, and d18:1/
24:1 values (considered as dependent variables), using diagnostic
groups (control subjects, MCI, and AD) and gender (males and
females) as independent variables. The statistical threshold used
in all ANOVAs was P < 0.05. Then, pairwise Fisher’s PLSD post hoc
tests were performed to assess differences in sphingomyelin spe-
cies between individual diagnostic groups. There was a signiﬁcant
overall effect of the diagnostic group only for d18:1/16:0
(F = 3.30; df = 2,75; P = 0.042), and d18:1/24:1 (F = 5.31; df = 2,75;
P = 0.007) and a signiﬁcant overall effect of gender for all sphingo-
lipids (F > 17.0, df = 1,75, P < 0.0001 for all effects). There was also a
signiﬁcant interaction between diagnostic groups and gender for all
sphingolipids (F > 12.0, df = 2,75, P < 0.0001 for all effects). In partic-
ular, all sphingolipid levels were reduced in females in comparison
withmales. Further, d18:1/16:0 levels were reduced inMCI females
(P < 0.026) and AD males (P < 0.014) in comparison with control
subjects. Last, d18:1/24:1 levels were reduced in MCI females
(P < 0.002) and AD males (P < 0.030) in comparison with control
subjects. We did not perform pairwise post hoc analyses of d18:1/
18:1 and d18:1/20:1 values because there was not an ANOVA over-
all effect of the diagnostic group for these sphingomyelin species.
These results are in good agreement with those previously pub-
lished by Han et al. [29], who reported that sphingomyelin species
d18:1/22:1 and d18:1/24:1 are lower in plasma of subjects with AD
(male plus female) relative to age-matched control subjects (n = 26
per group). It is important to point out that Han et al. did not sepa-
rate their analytical sample by gender: thus, the gender difference
potentially revealed by our analyses provides an element of novelty
that deserves further investigation.Conclusions
We describe a polarity-driven sample preparation protocol cou-
pled to orthogonal hydrophobic/hydrophilic liquid chromatogra-a samples from male and female patients with MCI or AD and age-matched healthy
owed by pairwise Fisher’s PLSD post hoc tests (⁄P < 0.05 vs controls).
54 Orthogonal LC-MS for plasma metabolomics / A. Armirotti et al. / Anal. Biochem. 455 (2014) 48–54phy, which allows for the untargeted and targeted metabolomic
investigation of human and mouse plasma. The analytes we
selected to test the new procedure (Table 2) represent a broad
range of LogP classes and metabolic pathways. Their wide LogP
span (3.87 to 10.77) demonstrates that virtually the entire chem-
ical space of plasma is accessible to LC–MS/MS in just a few analyt-
ical steps and at a reasonable sample consumption (0.1 ml). For
certain hydrophobic and hydrophilic analytes, the new protocol
performs better than two widely used protein precipitation meth-
ods (with acetonitrile or methanol). Notably, the paper-supported
version of the new protocol provides a valid analytical approach in
the midpolarity range. In case a higher coverage of such metabo-
lites is required, this option could be exploited with an acceptable
increase of sample preparation time. Our ﬁrst tests in human
plasma samples suggest that the procedure can be successfully
applied to the discovery of metabolomic alterations that accom-
pany disorders of human cognition, such as MCI and AD.
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